Global XDC 2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會通知

 
由藥明合聯(lián)WuXi XDC和佰傲谷BioValley共同主辦的2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會（Global XDC 2024），將于9月10-12日在無錫重磅回歸。大會涵蓋2個主論壇+4個分論壇，預(yù)計參會企業(yè)300+家，參會專家100+位，參會觀眾1000+人。大會以“探索偶聯(lián)藥的無限可能”為主題，將聚焦于新靶點發(fā)現(xiàn)與驗證、ADC和新型偶聯(lián)藥物創(chuàng)新技術(shù)、載荷-連接子新技術(shù)，以及CMC挑戰(zhàn)和商業(yè)化策略等內(nèi)容，探索前沿技術(shù)進步、分享國際優(yōu)秀生物科技公司的創(chuàng)新經(jīng)驗、引領(lǐng)ADC和XDC的新未來！
 
本屆峰會邀請了眾多生物偶聯(lián)藥領(lǐng)域的國際專家與會，共同探討創(chuàng)新合作，碰撞思想，助力生物偶聯(lián)藥行業(yè)蓬勃發(fā)展。
 
1.國際嘉賓陣容來襲，聆聽偶聯(lián)藥的世界聲音  
2.精選熱門議題一覽，探索偶聯(lián)藥的無限可能  
Keynote Speech
* Rina-S-the missing link(er) 
* Protein homeostasis by dual-precision targeted protein degradation and stabilization 
* A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs 
* MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
* NTX1105: development of a best-in-class ADC targeting Nectin-4 
* Collaborating within the global life science ecosystem to advance breakthrough science
 
論壇一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies
* Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
* Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
* Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker,   and dual payload system
* Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
* CS5001, a potential best-in-class ROR1 ADC
* Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
* Polysorbates in biopharmaceuticals-approaches to mitigate risk
 
論壇二：Bioconjugates development beyond ADCs
* RDC-the exploration of new drug modality in unmet clinical need
* Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
* GBB’s AI-enabled ecosystem elevating biological drug development
* Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
* Fully human common light chain technology for novel ADCs
 
論壇三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)
* Harnessing AbClick Pro® for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
* An overview on the new topoisomerases inhibitors technologies
* Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
* Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)
 
論壇四：CMC challenges and commercialization strategies
* CMC scale-up challenges and COGs for site specific ADCs
* Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
* The integrated analytical platform enables accelerated CMC development of XDCs
* QbD considerations for ADC process
* How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
* Non-clinical strategies for ADC drugs
 
3.歡迎更多XDC研發(fā)企業(yè)加入我們
主辦單位：藥明合聯(lián)WuXi XDC、佰傲谷BioValley
大會時間：2024年9月10-12日（周二/周三/周四）
大會地點：中國·無錫君來洲際酒店
參會報名：掃碼下方二維碼報名 聯(lián)系我們：
定制參展/商務(wù)合作請聯(lián)系：Stephen Sun 15966587556（微信同號）
參會報名/媒體合作請聯(lián)系：Abby Jiang 18217659261（微信同號） 4.特別感謝以下單位的支持